[
  {
    "ts": null,
    "headline": "Abbott, DexCom settlement ‘not a complete surprise,’ says Wells Fargo",
    "summary": "Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to resolve all outstanding patent litigation in the U.S. and Europe for 10 years. Under the agreement, both companies granted each other worldwide royalty-free, nonexclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing, including to all the patents asserted in the litigation. The firm had expected the parties",
    "url": "https://finnhub.io/api/news?id=d11bbba0268ded74f9c3e97e1f67546f2457820ab15ffe422af3864e1a7a7c1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735139722,
      "headline": "Abbott, DexCom settlement ‘not a complete surprise,’ says Wells Fargo",
      "id": 132160958,
      "image": "https://media.zenfs.com/en/tipranks_452/e1839507ce9d5542b9a5313ac8d70b9e",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to resolve all outstanding patent litigation in the U.S. and Europe for 10 years. Under the agreement, both companies granted each other worldwide royalty-free, nonexclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing, including to all the patents asserted in the litigation. The firm had expected the parties",
      "url": "https://finnhub.io/api/news?id=d11bbba0268ded74f9c3e97e1f67546f2457820ab15ffe422af3864e1a7a7c1e"
    }
  },
  {
    "ts": null,
    "headline": "DexCom, Abbott agree to settle patent litigation",
    "summary": "In a regulatory filing, DexCom (DXCM) stated: “As previously disclosed, DexCom has been involved in global patent litigation with Abbott (ABT) Diabetes Care and its affiliates. Both the Company and Abbott have accused the other of infringing certain patents, and each party has filed counterclaims and actions to invalidate the other party’s patents. On December 20, the Company and Abbott entered into a settlement and patent cross license agreement to resolve all outstanding patent litigation betw",
    "url": "https://finnhub.io/api/news?id=3d2643186f061e7fbe7a7dbcb01895a7339d14ae89a1a4ddc5e78fd617f3e8e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735122608,
      "headline": "DexCom, Abbott agree to settle patent litigation",
      "id": 132143142,
      "image": "",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "In a regulatory filing, DexCom (DXCM) stated: “As previously disclosed, DexCom has been involved in global patent litigation with Abbott (ABT) Diabetes Care and its affiliates. Both the Company and Abbott have accused the other of infringing certain patents, and each party has filed counterclaims and actions to invalidate the other party’s patents. On December 20, the Company and Abbott entered into a settlement and patent cross license agreement to resolve all outstanding patent litigation betw",
      "url": "https://finnhub.io/api/news?id=3d2643186f061e7fbe7a7dbcb01895a7339d14ae89a1a4ddc5e78fd617f3e8e4"
    }
  },
  {
    "ts": null,
    "headline": "Carillon Eagle Mid Cap Growth Fund Q3 2024 Commentary",
    "summary": "Mid-cap stocks improved notably during the third quarter, rebounding from the losses of the second quarter.",
    "url": "https://finnhub.io/api/news?id=ca00aa535df7587c0ee5139cba9ab6e20414fe92fc48538adfcfa42892b518fe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735113900,
      "headline": "Carillon Eagle Mid Cap Growth Fund Q3 2024 Commentary",
      "id": 132143752,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1562199023/image_1562199023.jpg?io=getty-c-w1536",
      "related": "DXCM",
      "source": "SeekingAlpha",
      "summary": "Mid-cap stocks improved notably during the third quarter, rebounding from the losses of the second quarter.",
      "url": "https://finnhub.io/api/news?id=ca00aa535df7587c0ee5139cba9ab6e20414fe92fc48538adfcfa42892b518fe"
    }
  }
]